Bellicum Pharmaceuticals
Houston
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $324.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2021)
- Ticker: nasdaq:BLCM
- Website: bellicum.com
- Phone: (832) 384-1100
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bellicum-pharmaceuticals-118012 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.